Humira Biosimilar Drumbeats: Biocon Claims Edge For Adalimumab In US

 
• By Anju Ghangurde

Biocon, which is set to close its deal with Viatris shortly, says it is in a “very good position” to vie for a share of the adalimumab biosimilar pie in the US and has had encouraging preliminary discussions with payers.

Biocon Well Placed To Debut Humira Biosimilar In The US • Source: Shutterstock

More from Business

More from Scrip